PWZ-029

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PWZ-029
PWZ-029 structure.png
Systematic (IUPAC) name
8-chloro-3-(methoxymethyl)-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
Clinical data
Legal status ?
Identifiers
CAS number  YesY
ATC code ?
PubChem CID 9971547
ChEMBL CHEMBL45346 N
Chemical data
Formula C14H14ClN3O2 
Mol. mass 291.732 g/mol
 N (what is this?)  (verify)

PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys,[1] It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.[2]

See also[edit]

References[edit]

  1. ^ US Patent application US2006/258643 A1
  2. ^ Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Research. 2008 May 7;1208:150-9. doi:10.1016/j.brainres.2008.02.020 PMID 18394590